You are here

News

Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells

Tuesday, March 18, 2014

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital’s Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

Cancer Stem Cell Consortium members congratulate Dr. John Dick on breakthrough research in leukemia and stem cells

Wednesday, February 12, 2014

Members of the Cancer Stem Cell Consortium (CSCC) today congratulated Dr. John Dick, a Senior Scientist at the University Health Network and Director of the Cancer Stem Cell Program of the Ontario Institute for Cancer Research, on major new findings published today in the journal Nature.

Canadian Club of Halton Peel dinner in Oakville on February 20 features guest speaker Dr. Pierre Meulien, PhD

Friday, February 7, 2014

The Canadian Club of Halton Peel has been presenting guest dinner speakers on a wide range of subjects since 1986.

Under the title “Our Personal Genome – The DNA Dilemma” Dr. Meulien will discuss the importance of Canadian genomic research in sectors such as health, agriculture, environment, forestry and fisheries. He will also address privacy issues arising from the sequencing of the human genome.

Date:                                 Thursday, February 20

Genomics Leading Innovation in BC

Monday, December 16, 2013

Seven new innovative research projects have been funded through Genome BC’s Strategic Opportunities Fund (SOF). The SOF program, with funding provided by Genome BC and several partners, aims to catalyze new projects and initiatives of strategic importance to BC’s economic sectors. These investments are increasingly recognized for providing foundational research and the projects provide an important basis for future research.

UCB Canada supports efforts to identify personalized treatment approach for drug-resistant epilepsy

Monday, December 9, 2013

Genome Canada and Génome Québec are pleased to announce UCB Canada Inc.’s contribution to a four-year study aimed at developing a personalized medicine approach to the early diagnosis of various types of epilepsy. The $10.8 million project, “Personalized medicine in the treatment of epilepsy”, forms the Canadian Epilepsy Network (CENet) and is led by Dr. Patrick Cossette at the University of Montreal Hospital Research Centre* (CRCHUM), as well as co-leaders, Dr.

Pages